Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30615514 | 1.00 | MAPT (0.60) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL3208590 | 0.89 | MAPT (0.66) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL2791114 | 0.89 | MAPT (0.66) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL26640038 | 0.86 | MAPT (0.73) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL2792580 | 0.85 | MAPT (0.56) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL30712110 | 0.83 | MAPT (0.54) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL17785078 | 0.82 | MAPT (0.53) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL29991845 | 0.81 | MAPT (0.70) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL29991732 | 0.81 | MAPT (0.70) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL21464265 | 0.81 | MAPT (0.65) | MAPTALDH1A1LMNAALOX12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885ALDH1A1 573/4885LMNA 4364/4885 |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | MAPT 3561/4885ALDH1A1 573/4885LMNA 4364/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885ALDH1A1 573/4885LMNA 4364/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | MAPT 1623/4885ALDH1A1 4726/4885LMNA 3635/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | MAPT 1623/4885ALDH1A1 4726/4885LMNA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.